Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, double-blind, placebo-controlled, multiple ascending dose, safety, tolerability, pharmacokinetic and central penetrance study of SRX251 capsules in healthy volunteers

Next Previous
Search
Trial Profile

Phase I, double-blind, placebo-controlled, multiple ascending dose, safety, tolerability, pharmacokinetic and central penetrance study of SRX251 capsules in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SRX 251 (Primary)
  • Indications Dysmenorrhoea; Premenstrual syndrome
  • Focus Adverse reactions

Most Recent Events

  • 12 Mar 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 02 Oct 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top